IL283771A - Anellosomes for delivering intracellular therapeutic modalities - Google Patents

Anellosomes for delivering intracellular therapeutic modalities

Info

Publication number
IL283771A
IL283771A IL283771A IL28377121A IL283771A IL 283771 A IL283771 A IL 283771A IL 283771 A IL283771 A IL 283771A IL 28377121 A IL28377121 A IL 28377121A IL 283771 A IL283771 A IL 283771A
Authority
IL
Israel
Prior art keywords
analosomes
delivery
therapeutic modalities
intracellular therapeutic
intracellular
Prior art date
Application number
IL283771A
Other languages
English (en)
Hebrew (he)
Original Assignee
Flagship Pioneering Innovations V Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flagship Pioneering Innovations V Inc filed Critical Flagship Pioneering Innovations V Inc
Publication of IL283771A publication Critical patent/IL283771A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5184—Virus capsids or envelopes enclosing drugs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/00023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/00041—Use of virus, viral particle or viral elements as a vector
    • C12N2750/00042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/00041—Use of virus, viral particle or viral elements as a vector
    • C12N2750/00043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Botany (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL283771A 2018-12-12 2021-06-07 Anellosomes for delivering intracellular therapeutic modalities IL283771A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862778851P 2018-12-12 2018-12-12
US201862778866P 2018-12-12 2018-12-12
PCT/US2019/065874 WO2020123753A2 (en) 2018-12-12 2019-12-12 Anellosomes for delivering intracellular therapeutic modalities

Publications (1)

Publication Number Publication Date
IL283771A true IL283771A (en) 2021-07-29

Family

ID=69160334

Family Applications (1)

Application Number Title Priority Date Filing Date
IL283771A IL283771A (en) 2018-12-12 2021-06-07 Anellosomes for delivering intracellular therapeutic modalities

Country Status (11)

Country Link
US (1) US20220040117A1 (enExample)
EP (1) EP3894567A2 (enExample)
JP (2) JP2022514501A (enExample)
KR (1) KR20210131308A (enExample)
CN (1) CN114127302A (enExample)
AU (1) AU2019396516B2 (enExample)
BR (1) BR112021009282A2 (enExample)
CA (1) CA3119339A1 (enExample)
IL (1) IL283771A (enExample)
MX (1) MX2021006941A (enExample)
WO (1) WO2020123753A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3121528A1 (en) 2018-12-12 2020-06-18 Flagship Pioneering Innovations V, Inc. Anellosomes and methods of use
JP2022513459A (ja) * 2018-12-12 2022-02-08 フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド タンパク質代替治療モダリティを送達するためのアネロソーム
AU2021288320A1 (en) * 2020-06-12 2023-01-19 Flagship Pioneering Innovations V, Inc. Tandem anellovirus constructs
US20240197823A1 (en) * 2021-02-12 2024-06-20 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Cationic antimicrobial peptides and uses thereof
TW202334423A (zh) 2021-12-15 2023-09-01 美商旗艦先鋒創新公司 表面經修飾之病毒顆粒及模組化之病毒顆粒
AU2023272105A1 (en) * 2022-05-19 2024-10-03 Flagship Pioneering Innovations V, Inc. Compositions comprising modified anellovirus capsid proteins and uses thereof
US20240415978A1 (en) * 2023-06-14 2024-12-19 Flagship Pioneering Innovations V, Inc. Anellovectors for delivery of effectors to the central nervous system
TW202529819A (zh) 2023-10-13 2025-08-01 美商旗艦先鋒創新公司 組織特異性指環載體(anellovector)遞送

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395472B1 (en) * 1999-02-05 2002-05-28 Abbott Laboratories Methods of utilizing the TT virus
CA3066750A1 (en) * 2017-06-13 2018-12-20 Flagship Pioneering Innovations V, Inc. Compositions comprising curons and uses thereof

Also Published As

Publication number Publication date
WO2020123753A2 (en) 2020-06-18
JP7898475B2 (ja) 2026-07-31
AU2019396516B2 (en) 2026-04-16
CA3119339A1 (en) 2020-06-18
JP2024102242A (ja) 2024-07-30
WO2020123753A3 (en) 2020-07-23
JP2022514501A (ja) 2022-02-14
US20220040117A1 (en) 2022-02-10
BR112021009282A2 (pt) 2021-08-17
CN114127302A (zh) 2022-03-01
KR20210131308A (ko) 2021-11-02
AU2019396516A1 (en) 2021-05-27
EP3894567A2 (en) 2021-10-20
MX2021006941A (es) 2021-11-17

Similar Documents

Publication Publication Date Title
IL283134A (en) Alcohol-resistant drug formulations
EP3866896A4 (en) PATIENT INTERFACE
EP3773843A4 (en) PATIENT INTERFACE
EP3691534C0 (en) ULTRASONIC THERAPY
HUE057877T2 (hu) Vegyületek és készítmények terápiás szerek intracelluláris bejuttatására
EP3629765A4 (en) DOSAGE ADMINISTRATION FILM
KR102199943B9 (ko) 의료용 자극 장치
PL3600309T3 (pl) Skojarzenia terapeutyczne do leczenia chorób wątroby
EP3840809A4 (en) PATIENT INTERFACE
IL283778A (en) Anellosomes for delivering secreted therapeutic modalities
DK3463465T3 (da) Exosomer omfattende terapeutiske polypeptider
HUE045043T2 (hu) Terápiás szerek neurodegeneratív betegségekre
HRP20190117T1 (hr) iRNK TERAPIJA ZA LIJEČENJE BOLESTI OKA
LT4331584T (lt) Lanifibranoro deuterintų darinių terapietiniai naudojimai
EP3761960C0 (en) OPHTHALMIC FORMULATION
IL282330A (en) Therapeutic compounds
EP3735463A4 (en) Cytotoxicity-inducing therapeutic agent
MA39483A (fr) Agents thérapeutiques cibles
IL260347A (en) Therapeutic anti-cd9 antibody
SI4119569T1 (sl) Konjugirane protismiselne spojine za uporabo v terapiji
EP3773844A4 (en) PATIENT INTERFACE
EP3860585A4 (en) Therapeutic compositions
EP3762079A4 (en) PATIENT INTERFACE
DK3408265T3 (da) Terapeutiske forbindelser
IL262851A (en) Combination prime: boost therapy